Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen Partners With Daiichi-Sankyo For Denosumab In Japan

This article was originally published in PharmAsia News

Executive Summary

Amgen and Daiichi-Sankyo have entered a collaboration and license agreement for development and commercialization of Amgen's investigational bone loss therapy denosumab in Japan, the companies announced July 11

You may also be interested in...



After A Dry 2013, Daiichi Sankyo Looks To Partners To Make It Rain

With only one deal in the last year, Daiichi Sankyo is ready for more deal-making with a new biz dev head and the acquisitions of oncology company Plexxikon and generics play Ranbaxy well behind it.

Daiichi Nets Novel HER-3 Antibody With U3 Acquisition

Daiichi Sankyo will acquire the privately held German biotech U3 Pharma in a €150 million ($233.9 million) deal that includes a novel HER-3 receptor antagonist partnered with Amgen

Daiichi Nets Novel HER-3 Antibody With U3 Acquisition

Daiichi Sankyo will acquire the privately held German biotech U3 Pharma in a €150 million ($233.9 million) deal that includes a novel HER-3 receptor antagonist partnered with Amgen

Related Content

UsernamePublicRestriction

Register

PS142217

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel